In today’s recent session, 1.63 million shares of the Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) have been traded, and its beta is 0.46. Most recently the company’s share price was $1.17, and it changed around -$0.03 or -2.50% from the last close, which brings the market valuation of the company to $22.07M. CMMB at last check was trading at a discount to its 52-week high of $2.55, offering almost -117.95% off that amount. The share price’s 52-week low was $0.87, which indicates that the recent value has risen by an impressive 25.64% since then. We note from Chemomab Therapeutics Ltd ADR’s average daily trading volume that its 10-day average is 0.11 million shares, with the 3-month average coming to 135.07K.
Chemomab Therapeutics Ltd ADR stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CMMB as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Chemomab Therapeutics Ltd ADR is expected to report earnings per share of -0.01 for the current quarter.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) trade information
Instantly CMMB has been showing red trend so far today with a performance of -2.50% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.2600 on recent trading dayincreased the stock’s daily price by 7.14%. The company’s shares are currently down -35.36% year-to-date, but still down -2.72% over the last five days. On the other hand, Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) is -15.83% down in the 30-day period. We can see from the shorts that 66042.0 shares have been sold at a short interest cover period of 0.63 day(s).
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 45.20%.
CMMB Dividends
Chemomab Therapeutics Ltd ADR’s next quarterly earnings report is expected to be released on 2025-May-15.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.27% of Chemomab Therapeutics Ltd ADR shares, and 25.38% of them are in the hands of institutional investors. The stock currently has a share float of 29.95%. Chemomab Therapeutics Ltd ADR stock is held by 19.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 0.7834% of the shares, which is about 2.24 million shares worth $2.05 million.
IKARIAN CAPITAL, LLC, with 0.0746% or 0.21 million shares worth $0.2 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
